Guerbet Announces U.S. Food and Drug Administration (FDA) Approval of Elucirem™ (Gadopiclenol) Injection for Use in Contrast-Enhanced MRI

Elucirem™ has the highest relaxivity compared to other non-specific GBCAs 1 Elucirem™ requires only half the gadolinium dose of conventional non-specific GBCAs Elucirem™ will be manufactured in Raleigh, North Carolina by Liebel-Flarsheim™ Company LLC, a Guerbet Group company. PRINCETON, N….

Click here to view original post